Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter AnalysisAdam S. Kittai, Alexey V. Danilov, Brian T. Hill et al.|Transplantation and Cellular Therapy|2020Cited by 60
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Reem Karmali, Lei Feng et al.|Journal of Hematology & Oncology|2023Cited by 52
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHLJoanna Zurko, Reem Karmali, Imran Nizamuddin et al.|Blood Advances|2022Cited by 50
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Alexey V. Danilov, Andy Kaempf et al.|Blood Advances|2023Cited by 49
Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.Lindsey Fitzgerald, Boyu Hu, Adam S. Kittai et al.|Journal of Clinical Oncology|2020Cited by 19